Sailing Boda

Sailing-Bio (Shanghai Sailing Biotechnology) is an innovative biopharmaceutical company specializing in the development of messenger RNA (mRNA) therapies and vaccines. Headquartered in Shanghai and backed by the Sailing Capital investment group (including the Sailing Boda funds), the company focuses on advancing its proprietary mRNA optimization and lipid nanoparticle (LNP) delivery platforms. Its pipeline is primarily directed toward oncology, featuring personalized cancer vaccines that target patient-specific neoantigens, as well as prophylactic vaccines for infectious diseases like COVID-19 and influenza. Sailing-Bio aims to address significant unmet medical needs by leveraging the rapid development and potency of RNA-based modalities. The company operates within a broader global investment ecosystem, positioning it to collaborate with international partners in the digital medicine and pharmaceutical sectors.